This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparative Study of Two Brands of Heparin Already on the Market

This study has been completed.
Information provided by:
Southlake Regional Health Centre Identifier:
First received: February 19, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
Two heparin brands have been in the market in Canada for several years. Heparin Leo from Leo Pharma and Hepalean from Organon. The former is standardized by B.P (British pharmacopeia) while the latter is standardized by U.S.P (United states pharmacopeia). Previous studies have shown Heparin Leo to have roughly a 10% less efficacy then Hepalean. It has also been demonstrated that more protamine is required to reverse Heparin Leo. It is the investigators' intention to study the post-operative effects of the two brands of heparin and whether one of the two causes less bleeding after bypass surgery.

Condition Intervention
Coronary Artery Bypass Grafting Drug: Heparin Leo and Hepalean

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: Do Different Heparin Brands Influence Bleeding in Coronary Surgery

Resource links provided by NLM:

Further study details as provided by Southlake Regional Health Centre:

Primary Outcome Measures:
  • Chest tube drainage [ Time Frame: 24 to 48 hrs ]

Secondary Outcome Measures:
  • Amount of heparin used [ Time Frame: 1 to 7 hrs ]
  • Amount of Protamine used [ Time Frame: 1 to 7 hrs ]
  • Measured slope with heparin/ACT titration [ Time Frame: 1 to 7 hrs ]

Enrollment: 100
Study Start Date: September 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Compare two market brands of Heparin
Drug: Heparin Leo and Hepalean
Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
Other Names:
  • Heparin Leo
  • Hepalean

  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Isolated Coronary Artery Bypass Surgery
  • Normal Hematocrit
  • Normal Creatinine
  • Normal Liver function

Exclusion Criteria:

  • Re-do
  • Combination procedure
  • Valve repair/replacement
  • IABP-pre/Intra/Post-op
  • Cell saver intra-op
  • Anemia (70 g/L)/Bleeding disorder, e.g.,: Jehovah's witness, hemophilia etc.
  • Use of aprotinin
  • Small adult < 50 kg
  • Aortic surgery with/without circ. arrest
  • Emergent patient with heart failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00848796

Canada, Ontario
Southlake Regional Health Centre
Newmarket, Ontario, Canada, L3Y 2P9
Sponsors and Collaborators
Southlake Regional Health Centre
Principal Investigator: Charles M Peniston, MD,FRCP Department of Cardiac surgery-S.R.H.C
  More Information

Responsible Party: Dr CM Peniston, Southlake Regional Health Centre Identifier: NCT00848796     History of Changes
Other Study ID Numbers: southlake
Study First Received: February 19, 2009
Last Updated: February 19, 2009

Keywords provided by Southlake Regional Health Centre:
Heparin Leo
CPB Cardiopuilmonary Bypass
CABG Coronary Artery Bypass Grafting
Anticoagulation efficacy

Additional relevant MeSH terms:
Calcium heparin
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 17, 2017